Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The specific aim of this Phase I/II study is to assess the safety of intravenous administered
Morpholino oligomer directed against exon 51 (AVI-4658 PMO).